FEBRUARY 2024 • VOLUME 24-03 PRESCRIBER EDITION



PharmacareNEWS

inside

Nova Scotia Formulary Updates

Criteria Update

Ozempic (semaglutide)

New Exception Status Benefit

• Rybelsus (semaglutide)

Nova Scotia Formulary Updates

Criteria Update

The following criteria has been updated and applies to new and existing products, effective **immediately.**

PRODUCT	Strength	DIN	PRESCRIBER	BENEFIT Status	MFR		
Ozempic (semaglutide)	2mg/3mL Prefilled Pen	02540258	DNP	E (SF)	NNO		
(semagrande)	2mg/1.5mL Prefilled Pen	02471477	DNP	E (SF)	NNO		
	4mg/3mL Prefilled Pen	02471469	DNP	E (SF)	NNO		
Criteria	• For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.						
	Claim Note:Approvals will be for a maximum of 1 prefilled pen every 4						
	weeks.						

New Exception Status Benefit

The following new products have been listed with the following criteria, effective immediately.

PRODUCT	STRENGTH	DIN	Prescriber	BENEFIT STATUS	MFR	
Rybelsus	3mg Tab	02497581	DNP	E (SF)	NNO	
(semaglutide)	7mg Tab	02497603	DNP	E (SF)	NNO	
	14mg Tab	02497611	DNP	E (SF)	NNO	
Criteria	• For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.					
	Claim Note:					
	Approvals will be for a maximum of one tablet per day.					

Legend

Pre	SCRIBER CODES	BE	NEFIT STATUS	MANUE	ACTURER CODES
D	- Physician / Dentist	S	- Seniors' Pharmacare	NNO	- Novo Nordisk Canada Inc.
Ν	- Nurse Practitioner	F	- Community Services Pharmacare		
Ρ	- Pharmacist		- Family Pharmacare		
М	- Midwife	С	- Drug Assistance for Cancer Patients		
0	- Optometrist	D	- Diabetes Assistance Program		
		Е	- Exception status applies		